Home・Elenco Azioni・Innoviva Inc

Innoviva Inc

Chiusa

SettoreSettore sanitario

21.18 2.52

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

20.51

Massimo

21.2

Metriche Chiave
By Trading Economics
Entrata	-270M -83M
Vendite	22M 120M
P/E Media del settore	4.754 57.002
EPS	0.59
Margine di Profitto	-69.754
Dipendenti	159
EBITDA	28M 267M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+96% upside

Dividendi
By Acuity
Utili prossimi	3 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-39M 1.5B
Apertura precedente	18.66
Chiusura precedente	21.18

Notizie sul Sentiment di mercato

By Acuity

67%

33%

302 / 340 Classifica in Healthcare

Innoviva Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 ago 2026, 19:56 UTC

Innoviva Inc shares are higher during Friday's session, recovering from earlier losses despite no specific news. Broader market sentiment is affected by declining U.S. retail sales.

13 ago 2026, 19:41 UTC

Innoviva Inc shares are lower during Thursday's session, with no specific news identified. The stock remains below its 20-day moving average.

12 ago 2026, 19:06 UTC

Event

Innoviva Inc's therapies are finalists for the 2026 Prix Galien USA Award, but shares are trading lower, remaining below Tuesday's close.

11 ago 2026, 19:16 UTC

Innoviva Inc's shares are higher in Tuesday's session, reflecting a modest gain since Monday's close. The stock remains below its 20-day moving average.

10 ago 2026, 19:16 UTC

News

Innoviva shares are higher despite mixed analyst ratings and a price target cut from Cantor Fitzgerald to $34.00. HC Wainwright maintains a $46.00 target.

7 ago 2026, 21:01 UTC

Innoviva Inc shares are lower in after-market hours, reflecting a decline since Friday's close and trading near the lower end of their one-month range.

6 ago 2026, 19:51 UTC

News

Innoviva Inc shares are higher as the company shifts to a diversified healthcare model, supported by $773 million in investments and positive momentum since Wednesday.

5 ago 2026, 21:01 UTC

Innoviva Inc shares are trading higher in after-market hours, recovering from a session low. No specific news was identified to explain the movement.

3 ago 2026, 19:46 UTC

News

Innoviva Inc shares are lower today, continuing a downward trend. Analysts from BTIG and HC Wainwright maintain buy ratings with targets of $42.00 and $46.00.

31 lug 2026, 20:06 UTC

Shares of Innoviva Inc. are trading lower, continuing a downward trend. The stock remains below its 20-day moving average amid no specific news.

30 lug 2026, 19:02 UTC

Innoviva Inc shares are declining amid market weakness and rising jobless claims. The stock remains near the lower end of its one-month range.

29 lug 2026, 19:06 UTC

Macro Event

Innoviva Inc shares are lower today as market scrutiny increases following the Federal Reserve's decision to maintain interest rates amid ongoing geopolitical tensions.

28 lug 2026, 20:03 UTC

Innoviva Inc shares are higher today, continuing an upward trend since Monday. No specific news was identified to explain the price movement.

27 lug 2026, 19:56 UTC

Innoviva Inc shares are lower today, reflecting broader market trends amid a significant drop in oil prices. No specific company news was identified.

21 lug 2026, 15:46 UTC

Innoviva Inc shares are higher today, reflecting a broader trend in rising equity indices. The stock remains below its 20-day moving average.

20 lug 2026, 18:31 UTC

Innoviva Inc shares are lower today, reflecting broader weakness in the Pharmaceuticals sub-sector. The stock has reversed from a recent trend of higher closes.

Confronto tra pari

Modifica del prezzo

Innoviva Inc Previsione

Obiettivo di Prezzo

By TipRanks

96% in crescita

Previsioni per 12 mesi

Media 40.67 USD 96%

Alto 46 USD

Basso 34 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Innoviva Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 3 che hanno fornito valutazioni azionarie a Innoviva Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

302 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.